Keros Therapeutics, Inc. announced on May 27, 2025, that Glass Lewis & Co., a leading independent proxy advisory firm, recommended that Keros stockholders vote 'FOR' all three of the company’s highly qualified director nominees. This recommendation is for the Annual Meeting of Stockholders scheduled for June 4, 2025.
Keros stated that Glass Lewis recognized the value its directors bring to the Board and understood that the Board and management team’s actions to maximize stockholder value are reasonable. The company emphasized that its Board is intentionally built with experienced individuals, many of whom directly represent stockholders.
The company also clarified that the Institutional Shareholder Services (ISS) recommendation to withhold votes from two directors was based on standard voting guidelines for 'uncontested' elections and did not address ADAR1 Capital Management’s specific allegations. Keros urged stockholders to protect their investment by voting 'FOR' its nominees.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.